- Home
- CNNE vs COLL Comparison
CNNE vs COLL Comparison
Compare CNNE & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNNE
- COLL
- Stock Information
- Founded
- CNNE 2014
- COLL 2002
- Country
- CNNE United States
- COLL United States
- Employees
- CNNE N/A
- COLL N/A
- Industry
- CNNE Restaurants
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- CNNE Consumer Discretionary
- COLL Health Care
- Exchange
- CNNE Nasdaq
- COLL Nasdaq
- Market Cap
- CNNE 1.1B
- COLL 958.8M
- IPO Year
- CNNE N/A
- COLL 2015
- Fundamental
- Price
- CNNE $18.85
- COLL $34.85
- Analyst Decision
- CNNE Buy
- COLL Strong Buy
- Analyst Count
- CNNE 3
- COLL 4
- Target Price
- CNNE $23.33
- COLL $44.25
- AVG Volume (30 Days)
- CNNE 570.1K
- COLL 324.7K
- Earning Date
- CNNE 11-11-2025
- COLL 11-06-2025
- Dividend Yield
- CNNE 3.21%
- COLL N/A
- EPS Growth
- CNNE N/A
- COLL N/A
- EPS
- CNNE N/A
- COLL 1.06
- Revenue
- CNNE $437,200,000.00
- COLL $707,007,000.00
- Revenue This Year
- CNNE N/A
- COLL $21.29
- Revenue Next Year
- CNNE N/A
- COLL $3.36
- P/E Ratio
- CNNE N/A
- COLL $33.34
- Revenue Growth
- CNNE N/A
- COLL 22.61
- 52 Week Low
- CNNE $15.92
- COLL $23.23
- 52 Week High
- CNNE $22.36
- COLL $39.95
- Technical
- Relative Strength Index (RSI)
- CNNE 53.71
- COLL 52.14
- Support Level
- CNNE $18.25
- COLL $31.26
- Resistance Level
- CNNE $18.87
- COLL $36.11
- Average True Range (ATR)
- CNNE 0.37
- COLL 0.92
- MACD
- CNNE 0.05
- COLL 0.32
- Stochastic Oscillator
- CNNE 83.33
- COLL 74.02
About CNNE Cannae Holdings Inc.
Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun & Bradstreet, Alight, BKFC, Corporate and Other. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.